about
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase IICardiac imaging approaches to evaluate drug-induced myocardial dysfunctionAssessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.Anthracycline cardiotoxicity: from bench to bedside.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer.Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.Anesthetic considerations for the pediatric oncology patient--part 3: pain, cognitive dysfunction, and preoperative evaluation.Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.How to monitor cardiac toxicity of chemotherapy: time is muscle!Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia.Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Comparison of estimates of left ventricular ejection fraction obtained from gated blood pool imaging, different software packages and cameras.Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin.Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor.Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
P2860
Q28473683-466E1528-2A9D-4E27-9489-CCCA8346F98EQ30446453-29BE923F-FB4F-472B-8BB5-FF66FDBBD93AQ30446509-97EAC65E-BC5D-4D6F-9905-B1CD70D2B02BQ33741091-0B06D05A-9A14-4F5B-B7C1-486764839276Q34477415-DC5963BB-29A5-4AA7-BFE7-30485696031EQ35008126-67A8B11C-5694-4BED-8005-96CC091D3097Q36806491-2A73ECF7-2DD1-41C6-B6B3-68EA9B7B500FQ36998127-E0D2BD04-A388-4E12-8C02-02E08EE56688Q37372203-A8BAE18E-CB3E-4534-B0EF-9264D02F7302Q37718942-9787345A-1337-4133-82B1-62F5BB38DFA5Q37924696-C249EA7E-4832-4F35-9637-AA237AB31DCCQ38171887-A91626DE-1B17-4DFE-983D-255D63CF1B6AQ38838517-F4B7296A-E56A-42D7-B418-4AEF30603EA9Q39198718-C4530493-B8BF-4A18-A0A7-206775286C20Q39416207-740F2954-0262-429F-9D88-AEA7D13CA613Q39759813-56DF0BB9-A4C6-4441-B3CB-1F9544DFC27CQ45925907-7A54A0A8-43D1-4352-ACE3-917F77E57C90Q51368192-FD8E8E48-5E0B-41C5-9113-D0A8D7B1ED2EQ55399510-E1EC3F77-8C9D-4E58-B3DA-6CA22C2F8E5EQ58091927-1DDCF7D5-022D-468A-B196-F9789EF4B7FB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monitoring of anthracycline-induced cardiotoxicity.
@en
Monitoring of anthracycline-induced cardiotoxicity.
@nl
type
label
Monitoring of anthracycline-induced cardiotoxicity.
@en
Monitoring of anthracycline-induced cardiotoxicity.
@nl
prefLabel
Monitoring of anthracycline-induced cardiotoxicity.
@en
Monitoring of anthracycline-induced cardiotoxicity.
@nl
P2093
P2860
P356
P1476
Monitoring of anthracycline-induced cardiotoxicity.
@en
P2093
Abigail Jannazzo
Janet Hoffman
P2860
P304
P356
10.1345/APH.1K359
P407
P577
2007-12-19T00:00:00Z